Literature DB >> 24880999

Is there always a need for invasive treatment of limited liver metastases in renal cell cancer or other solid tumors?

Frank Bruns1, Hans Christiansen.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24880999     DOI： 10.1007/s00345-014-1331-4

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  10 in total

Review 1.  A rationale for the targeted treatment of oligometastases with radiotherapy.

Authors:  Dhara M Macdermed; Ralph R Weichselbaum; Joseph K Salama
Journal:  J Surg Oncol       Date:  2008-09-01       Impact factor: 3.454

2.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  B Escudier; T Eisen; C Porta; J J Patard; V Khoo; F Algaba; P Mulders; V Kataja
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

Review 3.  The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies.

Authors:  Pierre Bigot; Souhil Lebdai; Alain Ravaud; Abdel Rahmène Azzouzi; Jean-Marie Ferrière; Jean-Jacques Patard; Jean-Christophe Bernhard
Journal:  World J Urol       Date:  2013-03-30       Impact factor: 4.226

Review 4.  Stereotactic body radiation therapy: a novel treatment modality.

Authors:  Simon S Lo; Achilles J Fakiris; Eric L Chang; Nina A Mayr; Jian Z Wang; Lech Papiez; Bin S Teh; Ronald C McGarry; Higinia R Cardenes; Robert D Timmerman
Journal:  Nat Rev Clin Oncol       Date:  2009-12-08       Impact factor: 66.675

5.  Clinical outcomes of single dose stereotactic radiotherapy for lung metastases.

Authors:  Mattia F Osti; Alessia Carnevale; Maurizio Valeriani; Vitaliana De Sanctis; Giuseppe Minniti; Enrico Cortesi; Massimo Martelli; Riccardo Maurizi Enrici
Journal:  Clin Lung Cancer       Date:  2013-07-22       Impact factor: 4.785

6.  Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study.

Authors:  Michael T Milano; Alan W Katz; Hong Zhang; Paul Okunieff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-13       Impact factor: 7.038

7.  Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.

Authors:  Rana R McKay; Nils Kroeger; Wanling Xie; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Mary J MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishampayan; Sun-Young Rha; Sumanta K Pal; Frede Donskov; Srinivas K Tantravahi; Brian I Rini; Daniel Y C Heng; Toni K Choueiri
Journal:  Eur Urol       Date:  2013-08-15       Impact factor: 20.096

8.  Treatment for liver metastasis from renal cell carcinoma with computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT): a case series.

Authors:  Dominik Geisel; Federico Collettini; Timm Denecke; Christian Grieser; Anne Flörcken; Peter Wust; Bernd Hamm; Bernhard Gebauer
Journal:  World J Urol       Date:  2012-11-07       Impact factor: 4.226

9.  Liver directed therapy for renal cell carcinoma.

Authors:  Russell C Langan; R Taylor Ripley; Jeremy L Davis; Peter A Prieto; Nicole Datrice; Seth M Steinberg; Gennady Bratslavsky; Udo Rudloff; Udai S Kammula; Alexander Stojadinovic; Itzhak Avital
Journal:  J Cancer       Date:  2012-04-20       Impact factor: 4.207

10.  High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.

Authors:  Won Il Jang; Mi-Sook Kim; Sun Hyun Bae; Chul Koo Cho; Hyung Jun Yoo; Young Seok Seo; Jin-Kyu Kang; So Young Kim; Dong Han Lee; Chul Ju Han; Jin Kim; Su Cheol Park; Sang Bum Kim; Eung-Ho Cho; Young Han Kim
Journal:  Radiat Oncol       Date:  2013-10-27       Impact factor: 3.481
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.